Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK/PD and efficacy of Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive anaemia in dialysis patients
2013-003585-14Phase 2Completed
- Sponsor
- TME Pharma
- Start
- Oct 2013
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anaemia and Functional iron deficiency (FID) comparing NOX-H94 arm with Placebo arm (2 arms). Primary endpoint: Incidence of adverse events. Started Oct 2013; status: completed.
02
Drugs
lexaptepid pegol
03
Conditions
anaemiaFunctional iron deficiency (FID)
Beyond the preview
Go deeper on 2013-003585-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003585-14.